Navigation Links
Researchers identify key role of microRNAs in melanoma metastasis
Date:7/11/2011

Researchers at the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, identified for the first time the key role specific microRNAs (miRNAs) play in melanoma metastasis to simultaneously cause cancer cells to invade and immunosuppress the human body's ability to fight abnormal cells. The new study is published in the July 11, 2011 issue of the journal Cancer Cell.

Researchers performed a miRNA analysis of human melanoma tissues, including primary and metastatic tumors. They found in both sets of tumor cells significantly high levels of a cluster of two miRNAs called miR-30b and miR-30d (miR-30b/30d). Higher levels of miR-30b/30d in melanoma tumor cells were linked to advanced stages of cancer, tumor progression, potential metastasis and reduced overall patient survival.

"Melanoma patients with higher levels of these miRNAs in their tumor cells are at greater risk for melanoma metastasis from their primary tumor," said Eva Hernando, PhD, senior author of the study and assistant professor in the Department of Pathology at NYU Langone Medical Center.

In the study, the benefit of silencing miRNAs in melanoma tumor cells was tested. This experiment led to the successful suppression of cell invasion, migration and metastatic melanoma. In addition, the study shows the over expression of miRNAs in tumor cells suppresses the normal function of GALNT7, an enzyme that modifies proteins on the surface of cells to control cell communication, cell migration and immune system surveillance. These miRNAs inhibit the role of GALNT7 in tumor cells leading to the spread of cancer.

"Our study results may have a direct clinical implication on the management of melanoma patients since these miRNAs can potentially serve as a new biomarker of a more aggressive tumor," said Avital Gaziel-Sovran, lead author of the study and NYU graduate student who conducted many of the experiments.

Melanoma is the deadliest form of skin cancer and one of the most invasive and aggressive tumor types. In the study, miRNAs were identified as strong promoters of the metastatic behavior of melanoma cells. miRNAs are the short pieces of RNA that regulate gene and cellular activities and are known to be linked to cancers like melanoma. However, this new research shows how these miRNAs increase melanoma cells' capacity to migrate, spread and metastasize.

"This study adds another piece to the melanoma puzzle showing how a few millimeter lesion on the skin's surface can quickly metastasize by invading other parts of the body like the lungs and brain so aggressively," said Dr. Hernando, a member of the Melanoma Program at the NYU Cancer Institute and the Center of Excellence on Cancers of the Skin at NYU Langone. "This study helps us better understand exactly why melanoma is so metastatic and suggests how miRNAs are a new potential therapeutic target for battling the disease."


'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. A change of heart: Penn researchers reprogram brain cells to become heart cells
2. Researchers identify early biomarker for future atopy in asymptomatic children
3. Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography
4. Leeds researchers test benefit of fish oil in bowel cancer spread
5. Fox Chase researchers identify new mechanism used by cells to reverse silenced genes
6. BUSM researchers find herbal medicine treatment reduces inflammation in allergen-induced asthma
7. Researchers at Oregon Health & Science University discover MS-like disease in monkeys
8. Drug shows improved kidney function for type 2 diabetics, UT Southwestern researchers report
9. Researchers identify components of speech recognition pathway in humans
10. Wayne State University researchers win grant from the NSF to target tinnitus
11. Researchers find CDT biomarker ineffective for identifying unhealthy alcohol use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... “Finn Mouseson”: follows the exciting story of a mouse as the need for ... a journey that will show that friends are to be gathered but home is ... illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts from the ...
(Date:9/20/2017)... ... September 20, 2017 , ... Ron Norman, CEO of Team ... week about the value of senior executives, pointed to a quote from William ... has brought us to the present and will lead us into the future," ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of ... is the creation of published author, Jeanine Liston, a busy mother of five who used ... “I have been writing this book for over twenty years. It was a way ...
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring a ... closets. “They Sang At Her Funeral” is the creation of published author, Annalise Harold, ... children and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate ...
(Date:9/19/2017)... ... 2017 , ... With a series of fundraising events, Fight ... in just a couple of weeks for those affected by Hurricane Harvey. After ... organizers expect to double those initial funds with the “Submit Harvey” online auction ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... -- For nearly two decades, New Life Agency has been committed to providing ... New Life Agency announces a powerful three-way partnership designed to deliver substantial ... ... http://www.schrafts2.com/ ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology: